leadf
logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals gets green light from data and safety board to continue Phase 2b-3 study

Algernon Pharmaceuticals (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to bring news the company has heard from the external Data and Safety Monitoring Board who has once again unanimously approved the continuation of the Company’s multinational Phase 2b/3 human study of Ifenprodil for the treatment of COVID-19.

Moreau talks about moving forward also about why he thinks this says about their drug compared to others.

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.29 CAD

CSE:AGN
Market: CSE
Market Cap: $31.92 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Algernon Pharma hits milestone in Phase 2b/3 human study of Ifenprodil...

Algernon Pharmaceuticals (CSE:AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to bring news the company has now enrolled 154 patients in its multinational Phase 2b/3 human study of Ifenprodil) for the treatment of COVID-19. Moreau telling Proactive they have...

5 days, 3 hours ago

2 min read